Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk's Latest Clinical Result Is Sending the Stock Plunging. Here's What Investors Need to Know.
07:07am, Monday, 01'st Dec 2025
Semaglutide failed to demonstrate slowed Alzheimer's progression in EVOKE/EVOKE+ preliminary results, though some biomarkers improved. Stock plunged intraday, then partly recovered; shares are down ~4
Novo Nordisk A/S $NVO Position Reduced by Boston Family Office LLC
03:32am, Monday, 01'st Dec 2025
Boston Family Office LLC trimmed its position in Novo Nordisk A/S (NYSE: NVO) by 5.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exch
Why Novo Nordisk Stock Just Hit a 4-Year Low
07:35pm, Saturday, 29'th Nov 2025
Novo Nordisk's trial to treat Alzheimer's with its GLP-1 drug failed. The company has been losing market share to Eli Lilly.
Benzinga Bulls And Bears: Alphabet, Reddit, Oklo — And Markets Bounce Bank On Rate Cut Hopes
08:01am, Saturday, 29'th Nov 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week - here's a look at some of our top stories.
Novo Nordisk A/S (NYSE:NVO) Given Average Recommendation of “Hold” by Brokerages
01:38am, Saturday, 29'th Nov 2025
Novo Nordisk A/S (NYSE: NVO - Get Free Report) has been assigned an average rating of "Hold" from the twenty-one analysts that are presently covering the company, MarketBeat reports. Two research anal
Novo Nordisk: Headwinds On The Surface, Deep Value If You Dig
10:32pm, Friday, 28'th Nov 2025
Novo Nordisk remains a Strong Buy despite recent earnings misses, trial setbacks, and competitive pressures in the weight loss/diabetes market. NVO's valuation is compelling, trading at a low P/E of 1
Novo Nordisk: A Textbook Value Trap
05:46pm, Friday, 28'th Nov 2025
Novo Nordisk A/S (NVO), though cheap at 13x forward earnings, is in my view a value trap, as growth is slowing and GLP-1 pricing pressures are capping revenue and profitability. The TrumpRx platform w
Novo Nordisk Stock Investors Get Huge News on Drug Trial Results
11:21am, Friday, 28'th Nov 2025
The company revealed critical information that investors will not want to miss.
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
12:55pm, Thursday, 27'th Nov 2025
PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.
Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy
12:26pm, Thursday, 27'th Nov 2025
NVO seeks an expedited FDA review for a higher 7.2 mg dose of Wegovy after strong weight-loss results in its STEP UP study.
Why Novo Nordisk Stock Is Moving Higher Today
02:48pm, Wednesday, 26'th Nov 2025
Novo Nordisk is seeking FDA approval for a 7.2 mg dose of Wegovy, nearly three times the current maximum dose. The application is under expedited FDA review, with a decision expected within one to two
Novo Nordisk Wants FDA Nod For A Higher-Dose Wegovy
01:27pm, Wednesday, 26'th Nov 2025
On Wednesday, Novo Nordisk A/S (NYSE: NVO) submitted its supplemental marketing application to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg for chronic
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
12:18pm, Wednesday, 26'th Nov 2025
The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced newly negotiated prices for 15 blockbuster drugs from
NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes
11:45am, Wednesday, 26'th Nov 2025
Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.
Novo Nordisk Seeks FDA Approval of Higher Dose of Wegovy Weight-Loss Shot
08:42am, Wednesday, 26'th Nov 2025
The Food and Drug Administration is set to treat application under its priority program that seeks to accelerate the review of products that address major health priorities.
